Breaking News
Get 40% Off 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did 😎 Read how
Close

Mabpharm Ltd (2181)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.395 0.000    0.00%
02/05 - Closed. Currency in HKD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.355 / 0.400
  • Day's Range: 0.365 - 0.395
Type:  Equity
Market:  Hong Kong
ISIN:  KYG5780F1046 
Mabpharm 0.395 0.000 0.00%

Mabpharm Ltd Company Profile

 
Get an in-depth profile of Mabpharm Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

347

Equity Type

ORD

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in the People’s Republic of China. The company’s products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for indications of rheumatoid arthritis, Crohn’s disease, etc; and CMAB807 for osteoporosis indications. It is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis. In addition, the company’s products under the pre-clinical stage include CMAB017 for the treatment of advanced solid tumors; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; CMAB022 for the treatment of inflammatory diseases; and CMAB023, a biosimilar drug candidate for Tezepelumab. Further, it is involved in research and development, manufacturing, technical consulting, technology transfer, and technical services of biological products, diagnostic reagents, chemical biological reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, China.

Contact Information

Address Block G79 Lujia Road East
Koutai Road West China Medical City Taizhou, 225300
China
Phone -
Fax -

Top Executives

Name Age Since Title
Liangzhong Guo 56 2018 Independent Non-Executive Director
Yanyun Zhang 65 2018 Independent Non-Executive Director
Hao Wang 52 2018 Chief Scientist, CEO & Executive Director
Yunfeng Li 44 2018 CFO, Joint Company Secretary & Executive Director
Jing Tao 50 2020 VP & Executive Director
Louis Ho Ming 40 2022 Independent Non-Executive Director
Shuge Jiao 57 2018 Non-Executive Chairman
Weizhu Qian 48 2023 Non-Executive Director
Sheng Hou 46 2023 VP & Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2181 Comments

Write your thoughts about Mabpharm Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email